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Although rhodopsin-like G protein-coupled receptors can
exist as both monomers and non-covalently associated dimers/
oligomers, the steady-state proportion of each form and
whether this is regulated by receptor ligands are unknown.
Hereinwe address these topics for theM1muscarinic acetylcho-
line receptor, a keymolecular target for novel cognition enhanc-
ers, by using spatial intensity distribution analysis. Thismethod
can measure fluorescent particle concentration and assess olig-
omerization states of proteins within defined regions of living
cells. Imaging and analysis of the basolateral surface of cells
expressing some 50 molecules m2 human muscarinic M1
receptor identified a75:25mixture of receptormonomers and
dimers/oligomers. Both sustained and shorter term treatment
with the selective M1 antagonist pirenzepine resulted in a large
shift in the distribution of receptor species to favor the dimeric/
oligomeric state. Although sustained treatment with pirenz-
epine also resulted in marked up-regulation of the receptor,
simplemass action effects were not the basis for ligand-induced
stabilization of receptor dimers/oligomers. The related antago-
nist telenzepine also produced stabilization and enrichment of
the M1 receptor dimer population, but the receptor subtype
non-selective antagonists atropine and N-methylscopolamine
did not. In contrast, neither pirenzepine nor telenzepine altered
the quaternary organization of the relatedM3muscarinic recep-
tor. These data provide unique insights into the selective capac-
ity of receptor ligands to promote and/or stabilize receptor
dimers/oligomers and demonstrate that the dynamics of ligand
regulation of the quaternary organization of G protein-coupled
receptors is markedly more complex than previously appreci-
ated. This may have major implications for receptor function
and behavior.
Encoded by single polypeptides that span the plasma mem-
brane seven times and frequently considered to be monomeric
entities, it is now well established that many class A, rhodopsin
family, G protein-coupled receptors (GPCRs)3 can formdimers
and/or oligomers when expressed in heterologous cell systems
(1, 2). There is also growing evidence that the samemay be true
in native tissues (1, 2). Despite this there are many questions
that remain unexplored or unresolved. These include the pro-
portion of a receptor population that is present in such quater-
nary complexes, how this is affected by receptor expression
level, and whether such complexes are regulated by interaction
with ligands or other receptor modulators.
The family of muscarinic acetylcholine receptors, of which
there are five subtypes in mammalian species (3), is a useful
example to illustrate each of these issues. For example, studies
on the muscarinic M2 receptor subtype have variously con-
cluded that it may be predominantly monomeric but with a
capacity to form dimers (4), is routinely dimeric (5), or is pre-
dominantly tetrameric (6). Similar variation has been reported
for each of themuscarinicM1 (5, 7) andM3 (8–11) subtypes. In
addition, although certain studies have indicated that addition
of muscarinic ligands does not affect the prevalence of receptor
dimers/oligomers (5, 12), other studies have indicated a capac-
ity for regulation. For example, the presence of muscarinic M2
receptor homomers increased, whereas co-expressed M2/M3
heteromers concomitantly decreased in parallel, in an agonist-
dependentmanner, in cells co-expressingM2 andM3 receptors
(13), and earlier studies had suggested that M3 receptor
homomers also either reorganized or were increased in amount
in response to agonist ligands (14). These latter studies were of
particular interest because the extent of the agonist-mediated
effect was greatest at lower receptor expression levels and less
marked at higher receptor expression levels (14). This suggests
that receptor expression level may indeed play a key role and
that mass action might drive dimer/oligomer production at
higher receptor expression levels.
Pirenzepine (11-[(4-methylpiperazin-1-yl)acetyl]-5,11-di-
hydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one) (Fig. 1) is a
particularly interesting ligand in the history of muscarinic
receptor pharmacology because it was the first antagonist
shown to have substantially different affinity at muscarinic
receptors in distinct tissues and in different regions of the cen-
tral nervous system (CNS). It was thus integral in defining that
there must be more than one subtype of muscarinic acetylcho-
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line receptor (15), an idea subsequently confirmed by cloning of
the distinct receptor subtypes (3). Pirenzepine displays sub-
stantially higher affinity for M1 thanM2 receptors. Pirenzepine
is also a medicine clinically used to treat gastric ulcers as is the
closely related molecule telenzepine (4,9-dihydro-3-methyl-4-
[4-methyl-1-piperazinyl)acetyl]-10H-thieno[3,4-b][1,5]ben-
zodiazepin-10-one) (Fig. 1). These are useful medicines
because their marked selectivity for the M1 receptor subtype
means that they do not significantly increase heart rate unlike
the subtype non-selective, antimuscarinic drugs including atro-
pine andN-methylscopolamine (Fig. 1) as this is anM2 subtype-
mediated response. Moreover, as they do not cross the blood-
brain barrier effectively, they also do not inhibit M1-mediated
cholinergic function in the CNS.
We have been exploring various approaches to define trans-
membrane protein organization and potential reorganization
(16, 17). Herein we examine effects of pirenzepine on human
M1 receptor quaternary organization by using confocal fluores-
cence imaging and then subjecting such images to spatial inten-
sity distribution analysis (SpIDA) (18–21).We show that treat-
ment of cells induced to express the human M1 receptor with
pirenzepine dramatically increases the proportion of dimeric/
oligomeric forms and that this is reversed following removal of
the ligand. We also show that pirenzepine-induced dimeriza-
tion is independent of a concomitant, marked increase in cell
surface level of the receptor that is produced with sustained
exposure to this ligand. Telenzepine, a closely related ligand
that has higher affinity for the M1 receptor than pirenzepine,
produced equivalent results, but interestingly the standard sub-
type non-selective antagonists atropine and N-methylscopol-
amine did not. Moreover, although pirenzepine and telenz-
epine can also bind to theM3muscarinic receptor, these ligands
did not produce such effects at theM3 receptor evenwhen used
at concentrations that fully occupy this receptor subtype.
Experimental Procedures
Materials—General laboratory chemicals as well as atropine
((RS)-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl) 3-hydroxy-2-phe-
nylpropanoate),N-methylscopolamine (NMS), cytochalasin D,
and both anti-tubulin antibody and secondary horseradish
peroxidase-conjugated antibody were from Sigma-Aldrich or
Fisher Scientific. DNA restriction endonucleases, calf intestinal
alkaline phosphatase, T4 DNA polymerase, and T4 ligase were
from New England Biolabs (Hitchin, UK). Wizard Plus SV
Miniprep kit was from Promega (Southampton, UK). NuPAGE
Novex precast 4–12% Bis-Tris gels and NuPAGE MOPS SDS
running buffer were from Invitrogen. QIAfilter Plasmid Maxi
kit, PCR purification kit, and QIAquick gel extraction kit were
fromQiagen (Crawley, UK). Agarose was from Flowgen Biosci-
ences (Nottingham, UK). The anti-GFP antiserum was gener-
ated in-house. ECL reagent was purchased from Pierce.
[3H]Quinuclidinylbenzilate ([3H]QNB) and [N-methyl-3H]sco-
polamine methyl chloride ([3H]NMS) were from PerkinElmer
Life Sciences. Other muscarinic ligands, specifically pirenz-
epine and telenzepine were from Tocris (Bristol, UK). Hanks’
balanced salt solution was from Life Technologies.
DNAConstructs—Enhanced green fluorescent protein incor-
porating an A206K mutation to reduce any tendency for the
fluorescent protein to homodimerize (monomeric enhanced
green fluorescent protein (mEGFP)) (22) was a gift from Dr. K.
Herrick-Davis (Albany, NY). To localize mEGFP to the plasma
membrane, a palmitoylation-myristoylation (P-M) sequence
(23) was added to the N terminus of the fluorescent protein as
described (24). hM1-mEGFPwas also a gift fromDr. K.Herrick-
Davis. hM3-mEGFP was made by subcloning PCR-amplified
hM3 between the SacI and BamHI sites of the mEGFP vector.
To allow the generation of inducible Flp-InTM T-RExTM sta-
ble cell lines, these constructs were all transferred from the
pEGFPN-1 plasmid (Takara Bio Europe/Clontech) backbone
to pcDNA5-FRT-TO (Invitrogen). This was done by excising
the appropriate region of the plasmid with NheI and NotI
and subcloning into the pcDNA5/FRT/TO vector at EcoRV-
NotI (after blunting the NheI site). All constructs were ver-
ified by sequencing.
Cell Lines—All cells weremaintained in a humidified incuba-
tor with 95% air and 5% CO2 at 37 °C. Parental Flp-In T-REx
293 cells (Invitrogen) were maintained in DMEM (high glu-
cose) supplemented with 10% (v/v) fetal calf serum, 100
unitsml1 penicillin, 0.1 mgml1 streptomycin, 10 gml1
blasticidin, and 100 gml1 Zeocin. Cell lines generated from
Flp-In T-REx 293 parental cells were maintained in DMEM
(high glucose) supplemented with 10% (v/v) fetal calf serum,
100 unitsml1 penicillin, 0.1 mgml1 streptomycin, 10
gml1 blasticidin, and 200 gml1 hygromycin.
Stable Cell Line Generation—Inducible Flp-In T-REx stable
cell lines able to express P-M-mEGFP, hM1-mEGFP, or hM3-
mEGFP were generated as described (24). After 48 h, the
medium was changed to medium supplemented with 200
gml1 hygromycin to initiate selection of stably trans-
fected cells. Pools of cells were established (10–14 days for
resistant colonies to form) and tested for inducible expres-
sion by the addition of 0.1 gml1 doxycycline for 48 h
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FIGURE 1. Structures ofmuscarinic antagonists. The chemical structures of
pirenzepine, telenzepine, atropine, and N-methylscopolamine are shown.
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followed by screening for fluorescence corresponding to
EGFP or by immunoblotting.
Cell Treatments—For antagonist treatments, cells were incu-
batedwith the appropriate concentration of compound for 16 h
at 37 °C. For cytoskeletal disruption studies, cells were incu-
bated with 2.5 gml1 cytochalasin D for 3 h at 37 °C.
Generation of Cell Lysates and Immunoblotting—Cells were
washed once in cold phosphate-buffered saline (PBS) (120 mM
NaCl, 25mMKCl, 10mMNa2HPO4, and 3mMKH2PO4, pH7.4)
and harvested with ice-cold radioimmunoprecipitation assay
buffer (50 mM HEPES, 150 mM NaCl, 1% Triton X-100, 0.5%
sodium deoxycholate, 10 mM NaF, 5 mM EDTA, 10 mM
NaH2PO4, and 5% ethylene glycol, pH 7.4) supplemented with
Complete protease inhibitor mixture (Roche Diagnostics).
Extracts were passed through a 25-gauge needle and incubated
for 15 min at 4 °C while on a rotating wheel. Cellular extracts
were then centrifuged for 10 min at 21,000 g, and the super-
natantwas recovered. Sampleswere prepared by the addition of
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) sample buffer and heated to 65 °C for 5min before
being subjected to SDS-PAGE analysis using 4–12% Bis-Tris
gels (NuPAGE; Invitrogen) andMOPS buffer. After separation,
the proteins were electrophoretically transferred to nitrocellu-
losemembrane, which was then blocked (5% fat-freemilk pow-
der in PBS with 0.1% Tween 20) at 4 °C on a rotating shaker
overnight. The membrane was incubated for 3 h with primary
antibody (1:10,000 sheep anti-GFP) in 2% fat-free milk powder
in PBS-Tween, washed (3  10 min with PBS-Tween), and
then incubated for 3 h with appropriate secondary antibody
(horseradish peroxidase-linked rabbit anti-goat IgG diluted
1:10,000 in 2% fat-free milk powder in PBS-Tween). After
washing as above, proteins were detected by enhanced
chemiluminescence (Pierce Chemical) according to the
manufacturer’s instructions.
Cell Membrane Preparations—Cells induced with the re-
quired concentration of doxycycline to express hM1-mEGFP or
hM3-mEGFP were washed and then harvested with ice-cold
PBS. Pellets of cells were frozen at80 °C for aminimumof 1 h,
thawed, and resuspended in ice-cold 10 mM Tris and 0.1 mM
EDTA, pH 7.4 (TE buffer) supplemented with Complete prote-
ase inhibitor mixture. Cells were homogenized on ice by 40
strokes of a glass-on-Teflon homogenizer followed by centrif-
ugation at 1000 g for 5 min at 4 °C to remove unbroken cells
and nuclei. The supernatant fraction was removed and passed
through a 25-gauge needle 10 times before being transferred
to ultracentrifuge tubes and subjected to centrifugation at
90,000 g for 30 min at 4 °C. The resulting pellets were resus-
pended in ice-cold TE buffer. Protein concentration was
assessed, andmembranes were stored at80 °C until required.
[3H]QNBBindingAssays—Both single concentration binding
studies and saturation binding curves were established by the
addition of 20 g of membrane protein to assay buffer (20 mM
HEPES, 100 mM NaCl, and 10 mM MgCl2, pH 7.5) containing
either a single, near saturating concentration (5 nM), or varying
concentrations of [3H]QNB (0.01–30 nM). Nonspecific binding
was determined in the presence of 10 M atropine. Reactions
were incubated for 120 min at 30 °C, and bound ligand was
separated from free by vacuum filtration through GF/C filters
(Brandel Inc., Gaithersburg, MD) that had been presoaked in
assay buffer. The filters were washed twice with cold assay
buffer, and bound ligand was estimated by liquid scintillation
spectrometry. Competition binding assays were carried out in a
similar way but with a constant concentration of [3H]QNB (1
nM) and the addition of a range of concentrations of ligands of
interest (0.03 nM–1 mM). Data were analyzed using GraphPad
Prism 5.03 (GraphPad Software, La Jolla, CA).
[3H]NMS Binding Assay—Flp-In T-REx 293 cells able to
express a construct of interest were grown overnight on white
96-well microtiter plates that had been treated with 0.1
mgml1 poly-D-lysine. Cells were then treated with various
concentrations of doxycycline for 24 h at 37 °C. The medium
was removed and replaced with 100 l/well cold PBS contain-
ing 1 nM [3H]NMS. Nonspecific binding was determined in the
presence of 10 M atropine. The plates were incubated at 4 °C
for 150 min, and the assay was terminated by removal of the
binding mixture followed by washing with 4  100 l/well
ice-cold PBS. One hundred microliters/well Microscint 20
(PerkinElmer Life Sciences) was added, and the plates were
sealed before overnight incubation at room temperature on a
rapidly shaking platform. Bound ligand was determined using a
Packard TopcountNXT (PerkinElmer Life Sciences). Using the
specific binding perwell andnumber of cells perwell, the recep-
tor copies per cell was determined.
Inositol Monophosphate Assay—Inositol monophosphate
accumulation assays were performed using Flp-In T-REx 293
cells able to express the hM3-mEGFP receptor construct in
an inducible manner. Experiments were performed using a
homogenous time-resolved FRET-based detection kit (CisBio
Bioassays, Codolet, France) according to the manufacturer’s
protocol. Cells were plated at 7500 cells/well in low volume
384-well plates, and the ability of various concentrations of the
agonist carbachol to increase the level of inositol monophos-
phate was assessed following incubation for 2 h with the ago-
nist. In appropriate experiments, this was preceded by a 15-min
preincubation with the indicated concentrations of antagonist
(atropine, pirenzepine, or telenzepine).
Monitoring of mEGFP Fluorescence Emission Spectrum—
Flp-In T-REx 293 cell lines able to express hM1-mEGFP were
grown to 100,000 cells/well in 96-well solid black bottom plates
(Greiner Bio-One) precoated with 0.1 mgml1 poly-D-lysine.
Cells were treated with 100 ngml1 doxycycline to induce the
expression of hM1-mEGFP. After 24-h induction, cells were
washed three times in Hanks’ balanced salt solution buffer. 100
l of Hanks’ balanced salt solution was added to each well,
and the plateswere read using aCLARIOstar fluorescence plate
reader (BMG Labtechnologies). Specifically, cells were excited
at 462 nm, and the emission spectrum between 500 and 600 nm
was collected at 5-nm intervals. The same process was repeated
after the addition to each well of 100 l of Hanks’ balanced salt
solution supplemented with the vehicle or the appropriate
muscarinic receptor antagonist.
SpIDA—SpIDA was carried out essentially as described (24).
All region of interest (RoI) measurements were selected from
the basolateral membrane surface. Monomeric equivalent unit
(MEU) values for hM1-mEGFP or hM3-mEGFPweremeasured
by normalizing their quantified quantal brightness (QB) values
Antagonist Reorganization ofMuscarinic Receptor Structure
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to average QB values measured from the P-M-mEGFP con-
struct using exactly the same laser power as used to excite
the muscarinic receptor subtype constructs. To distinguish
between monomeric and dimeric/oligomeric hM1-mEGFP or
hM3-mEGFP species, P-M-mEGFP MEU occurrence/fre-
quency x-y graphs (MEU bin size  0.1) were plotted for each
MEU value measured during excitation with laser power set to
2 or 6%. Such plots revealed a symmetrical distribution of the
values, and GraphPad Prism normality tests indicated the dis-
tributions were Gaussian (see “Results” and “Statistical Analy-
ses”). The data from each frequency x-y plot measured using 2
or 6% laser power were combined as this range of excitation
settings was required to illuminate the muscarinic receptor
subtypes optimally at differing expression levels without erro-
neous detector pixel saturation occurring. From this combined
plot, anMEU value of 1.274 (which represented 75% of the data
set, falling within the mean  1.5 standard deviations) was set
as a border to distinguish betweenmonomeric and larger com-
plexes in studies where individual MEU values exceeded 1.274.
Thedistributionof such values for themuscarinic receptor con-
structs was non-Gaussian and skewed toward higher values.
Calculation of Receptor Density at the Cell Surface by
SpIDA—SpIDA software also reports the mean fluorescence
intensity for each RoI analyzed. The number of hM1-mEGFP,
hM3-mEGFP, or P-M-mEGFP molecules/m2 (density) was
measured by dividing the mean fluorescence intensity value by
the quantified monomeric QB value.
Statistical Analyses—Variation in receptor number ormean/
median of QB produced by treatment with either ligands or
varying concentrations of doxycycline was assessed by one-way
analysis of variance with the use of Bonferroni’s or Dunnett’s
test for multiple comparisons as appropriate. Normality distri-
butions of recovered QB values defined asMEUs were assessed
by each of D’Agostino and Pearson, Kolmogorov-Smirnov, and
Shapiro andWilk normality tests (at p 0.05) and by skewness
and Kurtosis assessments. Distributions that failed any of the
three normality assessments (at p 0.05)were considered to be
non-Gaussian.
Results
A cDNA encoding A206K mEGFP that incorporated an
N-terminal addition of a plasma membrane-targeting P-M
sequence was cloned into the doxycycline-inducible Flp-In
T-REx locus of Flp-In T-REx 293 cells. Following addition of
doxycycline (10 ngml1) to these cells, a polypeptide of the
anticipated molecular mass (30 kDa) was identified by immu-
noblotting SDS-PAGE-resolved cell lysates with an anti-GFP
antiserum (Fig. 2A). Confocal imaging of the cells confirmed
plasma membrane targeting of the P-M-mEGFP construct fol-
lowing addition of doxycycline (Fig. 2B, panels i and ii). Imaging
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FIGURE 2. Expression, cellular distribution profile, and quantal brightness analysis of plasma membrane-targeted mEGFP. Flp-In T-REx 293 cells
harboring P-M-mEGFPweremaintained in the absence of doxycycline (Dox) or treatedwith doxycycline (10 ngml1) for 24 h (	Dox). Lysates of these cells
were resolved by SDS-PAGE and immunoblotted with an anti-GFP antiserum (A). In B, images of uninduced cells (panels i and iii) or cells induced to express
P-M-mEGFP (panels ii and iv) are shown. B, panels i and ii, confocal images across groups of cells. B, panels iii and iv, images of the basolateral surface of such
cells. C, panel i, shows QB assessed in individual RoIs (presented as monomeric equivalent units) plotted against number of mEGFP m2 of the basolateral
surface. Filled symbols, cells treatedwith 2.5 ngml1 doxycycline; open symbols, cells treatedwith 10 ngml1 doxycycline.C, panel ii, QB values from individual
RoIs were binned (bin size, 0.1 MEU), and these displayed a symmetrical distribution (see “Results”).
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RoIs of the basolateral membrane of these cells (Fig. 2B, panels
iii and iv) and subsequent analysis of such images by SpIDA (18,
19, 21, 24, 25) indicated that, with laser power set to 2%, this
polypeptide displayed QB of 12.15  0.39 units (mean 
S.E., n  76). Based on fluorescence intensity measurements,
in this set of studies the average expression level of P-M-
mEGFP within the basolateral membrane was 133.8  4.7
molecules m2 (mean  S.E., n  76) and in individual RoIs
this ranged between 46 and 232molecules m2 (Fig. 2C, panel
i). Variation in the concentration of doxycycline used can allow
control of the level of expression of the polypeptide harbored at
the Flp-In T-REx locus of such cells. Following treatment of
these cells with 2.5 ngml1 doxycycline, levels of expression of
P-M-mEGFP were lower, and appropriate analysis of confocal
images taken from the cells required laser power to be
increased. With laser power set to 6%, the P-M-mEGFP poly-
peptide displayed QB of 25.24  0.54 (mean  S.E., n  76)
with an average expression level of 62.1  2.2 molecules
m2. In individual RoIs, this ranged between 1 and 109
molecules m2 (Fig. 2C, panel i).
To assess whether P-M-mEGFP was detected as monomeric
across the full expression range achieved, we combined these
two data sets. This resulted in an average expression level of
99.0  3.9 molecules m2 (mean  S.E., n  152). Informa-
tion from each individual RoI was plotted as multiples of the
average QB, i.e. 12.15 or 25.24, respectively, for those obtained
with laser power set to 2 or 6%, and defined as MEU (Fig. 2C,
panel i). Analysis of this combined data set showed it to be
consistent with Gaussian distribution, and as such there was no
evidence to suggest that at higher levels of expression proximity
of individual molecules of P-M-mEGFP resulted in incorrect
assignment of these as being non-monomeric (Fig. 2C, panel ii).
Based on the distribution of values of MEU for P-M-linked
mEGFP that represented 75% of the data set, falling within the
mean  1.5 S.D., in subsequent studies we defined QB values
1.274 MEU as being monomeric, whereas QB values1.274
MEU were regarded as reflecting complexes that were larger
than monomers (Fig. 2C, panel ii) (see “Experimental Proce-
dures” for further details).
We next generated equivalent Flp-In T-REx 293 cells in
which cDNA encoding a form of the human M1 muscarinic
receptor with C-terminally fused mEGFP (hM1-mEGFP) was
cloned into the Flp-In T-REx locus. Once more this allowed
expression of the receptor construct only upon addition of
doxycycline with maximal expression obtained by use of 100
ngml1 doxycycline. The receptor was detected as a single spe-
cies, of apparent molecular mass close to 80 kDa, by immuno-
blotting lysates of untreated and doxycycline-treated cells
following resolution by SDS-PAGE (Fig. 3A). Fluorescence
intensity measurements of RoI from the basolateral membrane
of these cells indicated hM1-mEGFP to be expressed at 58.3
2.4 copies m2 (n 68) but with extremes of variation across
these RoIs of greater than 4-fold (Fig. 3B, panel i). SpIDA of the
images from these RoI, assessed at 2% laser power, indicated a
median QB of 13.85 units (n  68). This corresponds to 1.14
MEU (i.e. 1.14 MEU times the mean value of the monomeric
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FIGURE 3.hM1-mEGFP exists as amixture ofmonomers andoligomers in the basal state. Flp-In T-REx 293 cells harboring hM1-mEGFPweremaintained in
the absence of doxycycline ( Dox) or treated with doxycycline (100 ngml1) for 24 h (	 Dox). Lysates of these cells were resolved by SDS-PAGE and
immunoblotted with an anti-GFP antiserum (A). B, panel i, shows QB detected in individual RoIs (presented as monomeric equivalent units) plotted against
number of hM1-mEGFP m
2 of the basolateral surface (55.7 2.3m2,mean S.E.,n 68). B, panel ii, QB values from individual RoIswere binned (bin size,
0.2MEU). Thesedisplayedanon-symmetrical distribution skewed to values1.00MEU.Dotted line,median value.C, in this data set, 47of the68measurements
were assessed as being predominantly monomeric (69.1%).
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P-M-linked mEGFP). Here, however, distribution of the indi-
vidual observationswas non-Gaussianwith skew toward higher
values (Fig. 3B, panel ii). This is consistent with, at this expres-
sion level, the majority of the receptor construct being mono-
meric but with a proportion being within larger quaternary
structures, i.e. dimeric and/or oligomeric. The percentage of
hM1-mEGFP RoI QB values defined as “larger than monomer”
in this data set was 30.9% (Fig. 3C). Although verymodest (r2
0.032), over this limited range of expression levels, there was a
positive correlation between receptor number and the presence
of non-monomeric species observed in distinct RoIs (see later).
Although the number of observations in this specific data set
was restricted to 68, subsequently, at the completion of the
experimental studies, we combined the full data sets generated
for cells induced to express hM1-mEGFP but not further treated
(n  478). Analysis confirmed the non-Gaussian distribution of
the QB corresponding to hM1-mEGFP and allowed estimation of
the percentage of RoI QB values that were consistent with the
mean basal receptor being larger thanmonomer as 25.7%.
Pirenzepine (15) is the prototypic M1-selective muscarinic
receptor antagonist and has been reported to stabilize dimers of
this receptor (26). Competition binding experiments between
pirenzepine and the muscarinic antagonist [3H]QNB (Kd 
98  17 pM) allowed definition of the affinity of pirenzepine
(pKi  7.66  0.04) for the hM1-mEGFP construct (Fig. 4A).
Initially Flp-InT-REx 293 cells induced to express hM1-mEGFP
by treatment with 100 ngml1 doxycycline were incubated for
16 h with vehicle or with a single concentration of pirenzepine
(10M) calculated to be sufficient to occupy greater than 99%of
the receptor population. Imaging of these vehicle- and pirenz-
epine-treated cells illustrated a number of features. First, con-
focal images across the center of the cells showed that, as with
many GPCRs, although a substantial proportion of the hM1
receptor construct was located at the plasma membrane in
vehicle-treated cells, a significant fraction was inside the cells
and located within punctate vesicles (Fig. 4B, panel i). By con-
trast, following treatment with pirenzepine very little of the
receptor was detected within the cells, and the construct was
highly concentrated at the cell surface (Fig. 4B, panel ii). Imag-
ing of the basolateral surface of groups of these cells indicated
that there was marked up-regulation of hM1-mEGFP following
such sustained treatment with pirenzepine (Fig. 4C), and this
was confirmed in immunoblotting studies (Fig. 4D). Fluores-
cence intensity of RoI and associated SpIDAwithin the basolat-
eral membrane of such pirenzepine-treated cells indicated that
at 2% laser power the median QB of the receptor construct
(19.50 units, n  68, i.e. 1.61 MEU) increased markedly (p 
0.001) compared with the untreated cells (Fig. 4E). This was
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FIGURE 4. Sustained treatment with pirenzepine causes relocation and up-regulation of hM1-mEGFP and promotes oligomerization of the receptor.
Flp-In T-REx 293 cells harboring hM1-mEGFP were treated with doxycycline (100 ngml
1) for 24 h. A, membrane preparations from these cells were used in
ligand binding studies using 1 nM [3H]QNB and varying concentrations of pirenzepine. Based on the Kd for [
3H]QNB, estimated as 98 17 pM, the inhibition
constant (pKi) for pirenzepinewas calculated as 7.66 0.04. Shown is a representative graph fromn 3; error bars representS.E. Cellswere then treatedwith
vehicle (UT) or with pirenzepine (10M) for 24 h. B, panels i and ii, confocal images as in Fig. 2 showed that treatmentwith pirenzepine resulted in relocation of
hM1-mEGFP to enhance cell surface/plasma membrane localization. C, panels i and ii, imaging the basolateral surface of a group of cells indicated that
pirenzepine caused up-regulation of hM1-mEGFP. D, immunoblotting studies confirmed that pirenzepine caused up-regulation of hM1-mEGFP. -Tubulin
acted as a loading control. E, panels i–iii, quantal brightness and fluorescence intensity analysis from SpIDA confirmed an overall 2.1-fold up-regulation of
receptor number at the basolateral surface and that a substantially greater proportion of the RoIs were identified as containing dominantly receptor dimers/
oligomers (73.5%) following pirenzepine treatment (open symbols) than in vehicle-treated controls (30.9%) (filled symbols).
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consistent with a substantial increase (to 73.5%) in the percent-
age of RoI containing predominantly dimeric/oligomeric com-
plexes (Fig. 4E). Indeed, examination of the individual observa-
tions from distinct RoIs indicated a significant proportion of
these to be potentially consistent with the receptor existing in
complexes that were larger than dimers (Fig. 4E). Notably, the
effect of pirenzepine to both enhance QB of hM1-mEGFP (Fig.
5A) and increase the number of copies of the receptor construct
(Fig. 5B) was concentration-dependent with half-maximal
effect produced by close to 100 nM ligand.
Although the oligomeric organization of hM1-mEGFP was
clearlymore complex after sustained treatment of the cells with
pirenzepine, the correlation between receptor expression levels
and receptor quaternary complexity was now also markedly
increased (r2 0.22) compared with the untreated cells. How-
ever, we have shown previously that dimeric and oligomeric
organization of another class A GPCR, the serotonin 5-HT2C
receptor, increases simply with expression level of the receptor
(24). Therefore, because basolateral membrane receptor num-
ber was increased on average to 122.4  5.1 copies m2 fol-
lowing sustained pirenzepine treatment (Fig. 4D), it was im-
possible from these initial studies to determine whether piren-
zepine directly promoted and/or stabilized dimeric/oligomeric
forms of the hM1 receptor or whether receptor up-regulation
produced at the basolateral surface of the cells by treatment
with this antagonist ligandwas sufficient by itself to account for
these observations. A specific feature of the Flp-In T-REx locus
is that the level of expression of polypeptides can be controlled
by varying the concentration of doxycycline used (27). We,
therefore, treated cells harboring hM1-mEGFP at this locus
with a range of concentrations of doxycycline for 24 h. Immu-
noblotting SDS-PAGE-resolved lysates from these cells with
the anti-GFP antiserum showed variation in expression of the
receptor over the range 1–100 ngml1 doxycycline (Fig. 6A). In
parallel, binding of a near saturating concentration of [3H]QNB
tomembrane preparations of these cells provided confirmation
that the increasing immunological identification of the recep-
tor with doxycycline concentration was indeed consistent with
increasing numbers of receptors that could bind themuscarinic
antagonist (Fig. 6B). Based on these results, we selected to study
organization of hM1-mEGFP in cells treated with 2.5 ngml1
doxycycline. In such cells, analysis of basolateral RoIs con-
firmed that receptor expression was reduced (14.4  0.7
receptorsm2) compared with those treated with the
maximally effective concentration of doxycycline (Fig. 6C).
Although this level was significantly lower (p 0.001) than the
58.3  2.4 copies m2 recorded earlier in cells treated with
100 ngml1 doxycycline, this did not result in a significant
alteration in average QB and indicated that in both situations
the majority of the receptors were monomeric (Fig. 6C). Now,
although overnight treatment with pirenzepine (10 M) once
more significantly increased (p 0.001) receptor density (now
to 54.5 1.9 copies m2,n 70) at the basolateralmembrane
(Fig. 6C), it did so only to the same levels as present in cells
induced with 100 ngml1 doxycycline but not treated with
pirenzepine (i.e. 58.3  2.4 copies m2). QB and SpIDA
assessment now indicated that, at the same level of basolateral
cell surface expression of hM1-mEGFP, pirenzepine treatment
had indeed produced a substantial increase in overall receptor
complex organization as MEU increased to 1.73 (median). In
these experiments, following pirenzepine treatment the vast
majority of the RoIs (91.4%) had a higher average receptor olig-
omerization state than the monomer (e.g. dimeric/oligomeric),
whereas without pirenzepine treatment only in 30% of the RoIs
were there receptors thatwere not largelymonomeric (Fig. 6D).
We next considered whether shorter term treatment with
pirenzepine would also result in receptor dimerization/oligo-
merizationwithout causing the potentially confounding degree
of receptor up-regulation. For these studies, we used cells that
in the absence of pirenzepine had been induced to express the
receptor by treatment with 100 ngml1 doxycycline. In this set
of studies, analysis of RoI from the basolateral surface quanti-
fied the hM1-mEGFP receptor construct to be present at 41.8
1.3 copies m2 (n 134)with amedianMEUof 1.12 (Fig. 7A).
SpIDA indicated that in 26.9%of theRoI receptorswere present
dominantly within dimeric/oligomeric complexes. Treatment
of the cells with pirenzepine (10 M) for 90 min did result in a
small increase (p 0.01) in overall basolateral receptor density
to 54.1  1.7 copies m2 (n  134) (Fig. 7A). However,
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FIGURE 5. Pirenzepine-induced increases in both receptor oligomeriza-
tion and expression levels are concentration-dependent. Experiments
akin to those of Fig. 4 were performed on Flp-In T-REx 293 cells harboring
hM1-mEGFP that had been treated with doxycycline (100 ngml
1) for 24 h
and then treatedwith the indicated concentrations of pirenzepine. QB values
corresponding to hM1-mEGFP were plotted as monomeric equivalent units
against pirenzepine concentration (A) as were the number of receptor
molecules m2 (B). Data are presented as median (A) and mean (B). Error
bars representS.E.; n 84 in each case. UT, untreated.
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whether including the full data set (median QB after pirenz-
epine, 1.47 times MEU) or only a subset of the data in which
observations at receptor density levels of 80 copies m2
were excluded from the analysis, 63.4% of the RoIs now
reflected receptors dominantly in dimer/oligomer forms, a
major (p 0.001) increase over the untreated cells (Fig. 7A). To
assess the effect of pirenzepine further,we examined the revers-
ibility of the ligand-induced dimerization/oligomerization. Fol-
lowing treatment with pirenzepine for 90 min, the cells were
washed to remove ligand from themedium, and then the degree
of receptor complexity was assessed 90 min later to allow time
for bound pirenzepine to dissociate from the receptors. This
resulted in a dramatic reversal in the pattern of receptor com-
plexity (Fig. 7B) with now only 16.2% of the hM1-mEGFP RoIs
being defined as dimeric/oligomeric, a percentage that was not
different (p 0.05) from that observed in sets of untreated cells
that were analyzed in parallel (Fig. 7B).
Telenzepine is structurally closely related to pirenzepine
(Fig. 1) and is also an M1-selective antagonist. Competition
binding studies using [3H]QNB and telenzepine indicated that
telenzepine (pKi  8.33  0.04) displayed some 4-fold higher
affinity than pirenzepine (Fig. 8A). Telenzepine is also known to
dissociate slowly from the M1 receptor after binding. This fea-
ture allowed fluorophore-labeled forms of telenzepine to be
used tomonitor the distribution andmovement ofmolecules of
the M1 receptor expressed in CHO cells (7). Overnight treat-
ment with telenzepine (1M) of Flp-In T-REx 293 cells induced
to express hM1-mEGFP by treatment with 100 ngml1 doxy-
cycline also produced a very marked up-regulation (p 0.001)
of levels of the receptor as detected by both imaging the baso-
lateral surface of the cells (Fig. 8B, panels i and ii) and immu-
noblotting studies (Fig. 8C). Treatment with telenzepine also
enhanced quaternary structure complexity of the receptor (Fig.
8D) in this specific set of experiments from a very modest basal
level of 7.4% of RoIs that was consistent with the receptor being
in dimeric/oligomeric complexes to 60.3%. We also assessed
whether an equivalent effect was produced by a more tradi-
tional, non-subtype selective muscarinic antagonist. Atropine
is the prototypicmuscarinic blocker and, based on competition
with [3H]QNB to bind to the M1 receptor construct (Fig. 8A),
has high affinity for this receptor (pKi 9.06 0.04). Sustained
treatment of cells induced to express hM1-mEGFP with atro-
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boring hM1-mEGFPwere treatedwith varying concentrations of doxycycline (Dox).A, lysates from these cellswere immunoblottedwith an anti-GFP antiserum
to assess relative expression levels of the receptor construct. -Tubulin acted as a loading control. B, specific binding of a single near receptor saturating
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Shown are combined data from n 3 experiments; error bars representS.E. C, comparisons of QB (presented as monomeric equivalent units) and receptor
expression levels in cells induced to express hM1-mEGFP by treatment with 2.5 ngml
1 doxycycline (black symbols), treatment with 100 ngml1 doxycycline
(gray symbols), and after induction with 2.5 ngml1 and pirenzepine treatment (open symbols). D, in this data set, 91% of the RoIs contained a majority of
receptors present in dimeric/oligomeric form following treatment with pirenzepine (panel ii) but only 31 (panel iii) and 41% (panel i) in the absence of such
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pine (100 nM) also produced a significant (p 0.05) up-regula-
tion of the amount of the receptor construct at the basolateral
surface of these cells from 31.7  1.0 to 74.4  4.6
receptors m2 (Fig. 8B, panel iii), an effect that was also
detected in immunoblotting studies (Fig. 8C). However, analy-
sis by SpIDA showed that, in contrast with pirenzepine and
telenzepine, atropine treatment did not result in an overall
increase in the proportion of RoIs assessed as containing pre-
dominantly receptor dimers (Fig. 8E), although observation of
individual RoI did suggest the presence of a small proportion of
higher complexes (Fig. 8E). Based on this potentially surprising
difference, we also explored the effects of a further muscarinic
receptor subtype non-selective antagonist. We selected NMS
because it is structurally related to atropine. Competition bind-
ing studies with [3H]QNB indicated NMS to bind hM1-mEGFP
with high affinity (pKi 9.16 0.17 (Fig. 8A). Sustained treat-
ment of cells with NMS (50 nM) again produced a degree of
up-regulation of hM1-mEGFP levels as assessed by immuno-
blotting studies (Fig. 8C). However, as both imaging studies of
the basolateral membrane (Fig. 8B, panel iv) and quantification
of fluorescence intensity of imaged RoIs (Fig. 8F) did not dem-
onstrate this effect, it is assumed the extra copies of the receptor
detected by the immunoblotting reflect that the cellular loca-
tion of these are not within the basolateral membrane. Notably,
as for atropine, sustained treatment with NMS had very limited
effect on hM1-mEGFP quaternary organization (Fig. 8F).
The contribution of cytoskeletal structure to hM1-mEGFP
quaternary organizationwas then assessed by treatment of cells
induced to express hM1-mEGFPwith the actin-depolymerizing
agent cytochalasin D (2.5 gml1; 3 h). This treatment gener-
ated a number of challenges for SpIDA. As anticipated, this
treatment resulted in the cells becoming more rounded (Fig.
9A) and, as anticipated from this, having reduced basolateral
membrane contact with the glass coverslip (Fig. 9B). However,
following control measurements in cells induced to express the
P-M-mEGFP construct and similarly treated with cytochalasin
D, we were able to perform SpIDA studies (Fig. 9C). Treatment
with cytochalasin D for this period did not up-regulate basolat-
eral levels of hM1-mEGFP (Fig. 9C) but did increase receptor
quaternary structure complexity (Fig. 9C). Interestingly, using a
very different approach, a similar observation has been made
for the serotonin 5-HT1A receptor (28).
Although pirenzepine and telenzepine are M1-selective
antagonists, they also can interact with othermuscarinic recep-
tor subtypes. The M3 receptor is closely related to the M1 sub-
type and also signals selectively via Gq/G11 family G proteins.
An M3 muscarinic receptor construct (hM3-mEGFP) akin to
hM1-mEGFP was generated and cloned into the Flp-In T-REx
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versus 27%) (panels ii and iii). B, following washing of cells that had been exposed to pirenzepine (open symbols) or untreated (filled symbols), quaternary
organization was assessed 90 min later (panel i). In this study, 25% of RoIs from the previously untreated cells were now estimated to have hM1-mEGFP in
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locus of Flp-In T-REx 293 cells to allow doxycycline-controlled
regulation of expression (Fig. 10A). The overall size of the M3
receptor is considerably larger than the M1 subtype, largely
because of a markedly longer third intracellular loop. As such,
the apparent molecular mass of this construct (approximately
140 kDa) was much greater in anti-GFP immunoblots of SDS-
PAGE-resolved lysates of these cells (Fig. 10A). [3H]NMS is
a high affinity muscarinic antagonist that, because it is hy-
drophilic and, therefore, does not easily cross the plasma
membrane of intact cells, can be used to identify cell surface
muscarinic receptors. Specific binding of a near saturating con-
centration of this ligand also confirmed doxycycline con-
centration-dependent expression of hM3-mEGFP (Fig. 10B).
Confocal imaging of cells induced to express hM3-mEGFP
indicated that most of the receptor was present at the plasma
membrane, in this case even without treatment with an antag-
onist ligand (Fig. 10C). As anticipated for a Gq/G11-coupled
receptor, the muscarinic agonist carbachol stimulated produc-
tion of inositol phosphates in a concentration-dependent fash-
ion in cells induced to express hM3-mEGFP but not in cells that
were not pretreated with doxycycline (Fig. 10D). Competition
binding studies using [3H]QNB (Kd for hM3-mEGFP 0.28
0.05 nM) allowed estimation of the affinity of pirenzepine (pKi
 5.92  0.09), telenzepine (pKi  7.15  0.02), and atropine
(pKi  7.97  0.06). Importantly, at concentrations assessed
from [3H]QNB competition binding experiments to be at least
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FIGURE 8. Telenzepine, but not atropine orN-methylscopolamine, also promotesM1 receptor oligomerization. As in Fig. 3, cells harboring hM1-mEGFP
were treated with 100 ngml1 doxycycline for 24 h to induce expression of the receptor construct. A, membrane preparations from these cells were used in
ligand binding studies using a fixed concentration of [3H]QNB (1 nM) and varying concentrations of either telenzepine (open circles), atropine (open squares), or
N-methylscopolamine (filled circles). Shown are representative plots from n 3; error bars representS.E. B, images of the basolateral surface of cells treated
with vehicle (UT) (panel i), telenzepine (panel ii), atropine (panel iii), or NMS (panel iv). C, immunoblotting of cell lysates confirmed up-regulation of hM1-mEGFP
following treatmentwith telenzepine (panel i, lane 3), atropine (panel i, lane 4), orN-methylscopolamine (panel ii, lane 7). Cell lysate fromuninduced cells (panel
i, lane 1 and panel ii, lane 5) and from cells treated with the vehicle (panel i, lane 2 and panel ii, lane 6) were also loaded for comparison. Detection of -tubulin
acted as a loading control.D, E, and F, comparisons of QB (presented asmonomeric equivalent units) and receptor expression levels in cells induced to express
hM1-mEGFPby treatmentwith 100ngml
1 doxycycline thatwere thenuntreated (filled symbols) or treatedwith 1M telenzepine (D,panel i,open symbols), 0.1
Matropine (E,panel i,open symbols), or 0.05MN-methylscopolamine (F,panel i,open symbols) for 16h.Although treatmentwith telenzepineproduceda large
increase in the proportion of RoIs containing predominantly receptor dimers/oligomers (D, panels ii and iii), atropine (E, panels ii and iii), and N-methylscopol-
amine (F, panels ii and iii) did not.
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100 timesKi, each of pirenzepine (200M), telenzepine (10M),
and atropine (10 M) fully blocked carbachol-induced inositol
phosphate generation (Fig. 10D). Notably, unlike the hM1-
mEGFP construct, sustained treatment with any of these three
antagonists at these concentrations failed to up-regulate levels
of hM3-mEGFP whether assessed via immunoblotting studies
performed on cell lysates (Fig. 10E) or by direct observation of
the basolateral surface of the cells (Fig. 10F).
When these cellswere induced to express hM3-mEGFPusing
a maximally effective concentration of doxycycline (100
ngml1), expression at the basolateral surface wasmeasured to
be 40.3  2.6 copies m2 (Fig. 11A). The median QB corre-
sponded to 1.08 MEU (n 132) (Fig. 11B). SpIDA of the indi-
vidual observations indicated that in 81.1% of the RoIs the
receptor was predominantly monomeric. Analysis of RoIs fol-
lowing sustained treatment with each of pirenzepine, telenz-
epine, and atropine confirmed that these ligands did not alter
themean expression levels of hM3-mEGFP (Fig. 11A), andneither
did they alter the QB observed (Fig. 11B). Moreover, analysis of
individual observations did not support any regulation of the hM3
receptor monomer-oligomer distribution (Fig. 11,C andD).
Discussion
Although it is well established thatmonomers ofmembers of
the rhodopsin-like, class A group of GPCRs can interact to gen-
erate dimers and/or higher order oligomers (1, 2), issues relat-
ing to the stability or otherwise of such interactions and how
this might vary between both different receptors and in cells
and tissues expressing different amounts of an individual recep-
tor remain unresolved. Thus, although the formyl peptide
receptor 1, when present in CHO cells at rather low expression
levels, has been observed to interconvert between monomers
and dimers with subsecond kinetics (29) and the hM1 receptor
expressed in CHO cells has also been reported to exist as a
rapidly interconverting mixture of monomers and dimers (7),
the technical approaches used in these studies rely on and
require low level expression. At the other extreme, concerns
have been raised over the possibility that certain studies on the
organizational structure of class A GPCRs have used high level
receptor “overexpression” that might have produced outcomes
in terms of receptor-receptor interactions that are not of phys-
iological relevance (1, 2). However, it is important to note that,
particularly in the CNS, ligand binding studies performed on
membranes generated from bulk tissue have indicated that
receptors such as the M1 muscarinic receptor are expressed, in
striatum for example, at levels of at least 1 pmolmg of mem-
brane protein1 (15), and this is presumably higher in cells that
actually express the receptor, whereas other GPCRs, including
cannabinoid and opioid receptors, are expressed regionally at
significantly higher levels. It has also been suggested that recep-
tor organizational complexity may increase with expression
levels. Indeed, Calebiro et al. (30) observed just such a relation-
ship for both the 1- and 2-adrenoceptors following expres-
sion inHEK293 cells andwere able to detect increasing propor-
tions of both dimers and oligomers of each receptor. Equally, a
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similar relationship between receptor expression level and qua-
ternary complexity has also been observed for the serotonin
5-HT2C receptor (24). As such, based solely on mass action,
then in a number of natively expressing systems, GPCRs may
potentially be at least partially dimeric and/or oligomeric.How-
ever, it is important to note that others have suggested more
stable oligomeric organization over a significant range of
expression levels. For example, Herrick-Davis et al. (5) have
indicated that over a 10-fold range of expression, between
26,000 and 260,000 copies per cell, theM1 receptor expressed in
HEK293 cells is consistently dimeric, and Guo et al. (31) sug-
gested that over a 100-fold range of expression levels dopamine
D2 receptors had cross-linking characteristics consistent with
them forming and remaining as tetramers. This, however, is in
contrast to other studies of the dopamine D2 receptor suggest-
ing that “dimeric” interactions might, at best, be transient (32).
Moreover, although at odds with earlier studies indicating that
the serotonin 5-HT2C receptor is also dimeric when expressed
in HEK293 cells (33) and indeed is also reportedly dimeric in
epithelial cells from choroid plexus where endogenous expres-
sion was estimated to be 32 receptors m2 on the apical sur-
face (34), Ward et al. (24) noted that at expression levels above
100 receptors m2 on the basolateral surface of HEK293 cells
much of the 5-HT2C receptor was present within higher order
oligomers rather than dimers and that at expression levels
below 50 receptors m2 a significant proportion of this recep-
tor was monomeric.
Herein we note in the basal state and at moderate expression
levels in HEK293 cells that, although the larger proportion of
the hM1 receptor is monomeric, there is a clear fraction of
dimeric forms. Moreover, treatment of the cells with the mus-
carinic M1 receptor-selective antagonist pirenzepine resulted
in a substantial increase in the proportion of dimeric, as well as
oligomeric, forms. This is interesting from three distinct per-
spectives. First, these results are in agreement with those of
Ilien et al. (26), who, by using two-photon fluorescence corre-
lation spectroscopy in cells expressing an N-terminally fluores-
cent protein-tagged variant of the hM1 receptor, were able to
observe a rapid, pirenzepine-induced transition from a situa-
tion in which the receptor was predominantly monomeric to a
mixture of monomers and dimers. Second, although sustained
treatment of cells with pirenzepine produced amarked up-reg-
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ulation of the basolateral levels of hM1 receptor thatmight have
confounded interpretation of the effect of the antagonist, this
concernwas overcome by having the receptor expressed from a
doxycycline-regulated locus whereby we were able to define
conditions in which the number of receptors after sustained
treatment with pirenzepine was not different from vehicle-
treated cells. In this situation, there was also clearly a much
greater proportion of hM1 dimers detected after pirenzepine
treatment. This demonstrated explicitly that although pirenz-
epine treatment does up-regulate levels of the receptor, which
inherently increases the proportion of receptor dimers/oligo-
mers, it also stabilizes receptor dimers in a manner-indepen-
dent from this. It is also important to note that for the P-M-
mEGFP construct, at levels well above those used to study the
muscarinic receptors, this polypeptide was identified exclu-
sively as being monomeric. Therefore, simple aspects of prox-
imity at the levels of expression used for the hM1 did not result
in artifactual identification of apparently dimeric species. Third
and perhaps most intriguingly, pirenzepine is structurally very
closely related to telenzepine. A fluorophore-tagged form of
telenzepine was used by Hern et al. (7) to labelM1 receptors for
total internal reflection microscopy studies that allowed track-
ing and analysis of receptor monomers and dimers. As we note
herein, as for the fluorescent form of telenzepine, which was
used at high receptor occupancy by Hern et al. (7), native telen-
zepine caused both substantial up-regulation of the hM1 recep-
tor and promoted the presence of dimers. As such it is likely
that Hern et al. (7) may have inadvertently generated a greater
proportion of receptor dimers simply by their choice of fluores-
cent antagonist. A further fascinating feature of the studieswith
pirenzepine and telenzepine was that the effect of these ligands
was not mimicked by the structurally distinct muscarinic
antagonists atropine andNMS. Further studies will be required
to unravel themolecular basis for these differences. One poten-
tial confounding issue for these studies would have been
whether addition of pirenzepine and telenzepine altered the
spectral characteristics of mEGFP. We tested this directly and
observed no effect.
A further key point from these studies is that the effect of
pirenzepinewas reversible. Following removal of the ligand, the
M1receptorpopulationreturnedtobeingpredominantlymono-
meric. Although this is clearly the case, it was not realistic to
accurately define the time course of this process. This reflects
that, as a relatively high affinity antagonist for the hM1 receptor,
pirenzepine has a significant residency time on the receptor. As
such, simply washing cells to remove bulk ligand from the
medium does not intrinsically remove the ligand from the
receptor. Indeed, the slow dissociation rate of telenzepine from
the M1 receptor was a key reason for Hern et al. (7) to select a
fluorescent variant of telenzepine for their receptor tracking
studies. Identification of a ligand that mimics the capacity of
pirenzepine to promoteM1 receptor dimerization but has rapid
“off”-rate binding kinetics will be required, therefore, to start to
define the true rate of hysteresis of M1 receptor quaternary
complexes back to monomers in the absence of ligand.
Integral to the studies we have performed, SpIDA has been
shown previously to be able to observe and quantify ligand-
induced alterations in quaternary structure and organization of
various classes of transmembrane receptor proteins. For exam-
ple, using this method, we have shown that addition of epider-
mal growth factor results in rapid and ligand concentration-de-
pendent dimerization of the epidermal growth factor receptor
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(24). Moreover, although SpIDA demonstrated the single
transmembrane domain axonal guidance receptor Robo-1 to
exist basally as a dimer and that this organization was unaf-
fected by addition of the ligand Slit-2 (25), in terms of GPCRs,
higher order oligomers and even dimers of the serotonin
5-HT2C receptor were pushed towardmonomeric organization
upon binding of antagonist ligands from two distinct chemo-
types (24). Furthermore, washing of the cells to remove bulk
ligand from the medium allowed a time-dependent hysteresis
of quaternary complexity back toward the basal state (24).
Interestingly, ligand effects on receptor quaternary organiza-
tion are clearly rather selective. The M3 muscarinic receptor is
closely related to theM1 receptor and can also bind pirenzepine
although with somewhat lower affinity. Pirenzepine did not
produce an equivalent effect on theM3 receptor, however, even
when the ligandwas present at concentrations sufficient to fully
occupy the M3 receptor population. The molecular basis for
this distinction will require many further studies, including
potentially the generation of receptor point mutants and chi-
meras between these subtypes.
The current studies highlight that the quaternary organiza-
tion of class A GPCRs can indeed be regulated by ligand bind-
ing. Given that pirenzepine and telenzepine enhance this com-
plexity for the hM1 receptor, whereas a group of antagonists
decreased complexity of the serotonin 5-HT2C receptor (24),
then it will be important to explore this issue for other GPCRs
in a systematic manner to begin to understand the molecular
basis for these observations.Although in certainGPCRs a single
transmembrane domain appears to provide a key symmetrical
interface for receptor dimerization, e.g. transmembrane
domain IV of the secretin receptor (35), studies on many
GPCRs have concluded that multiple regions contribute (8, 11,
36). This has resulted in suggestions that there may bemultiple
ways in which receptor dimers can form, and the stability of
these distinct forms may well differ (8, 37, 38). Moreover, there
are suggestions, based particularly on receptor cross-linking
studies, that ligands with different functionalities, e.g. agonists
versus inverse agonists (39), alter details of the organization of
receptor-receptor interfaces. This might well be anticipated to
modify the affinity of interaction between the individual
protomers and, therefore, the balance of observed quaternary
structures. Clearly this is speculative, but as various mutations
also alter the effectiveness of receptor dimerization and oligo-
merization (35–36) it would be likely that ligand effects at such
mutants might be further amplified. These topics will form the
basis of future studies.
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